Gregory Grunberg is Director at Kala Pharmaceuticals, Inc. (KALA). They have made 6 open-market trades across 2 companies since 2017, most recently 2021-06-17.
CIK 0001711080
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
5 open-market purchases totalling $60.4M since 2017, against 1 sale. Across 5 scored buys the stock is up 16.3% at ninety days, and 9.2 points ahead of the S&P over the same stretch.
5 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 80% | 60% | 40% |
| Avg Move | +15.6% | +20.3% | +16.3% |
| Alpha | +14.9% | +16.9% | +9.2% |
| Scored | 5 | 5 | 5 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ETNB | SELL | 2021-04-21 | 2021-04-23 | $27.60 | $23K | -7.5% | -25.2% | -33.7% |
| ETNB | BUY | 2020-07-10 | 2020-07-14 | $27.50 | $3.0M | -2.9% | -5.7% | -26.9% |
| KALA | BUY | 2020-03-13 | 2020-03-16 | $7.89 | $40.0M | +19.3% | +52.0% | +110.7% |
| ETNB | BUY | 2019-11-11 | 2019-11-13 | $16.00 | $9.2M | +47.8% | +52.7% | +37.8% |
| KALA | BUY | 2018-10-05 | 2018-10-09 | $8.25 | $5.0M | +8.7% | -9.9% | -27.1% |
| KALA | BUY | 2017-07-25 | 2017-07-26 | $15.00 | $3.2M | +5.1% | +12.4% | -13.2% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.